FF-21101In

N/A

Report date: 2025/11/21 17:15:31

Base Information

Drug NameFF-21101In

Drug Alias NameFF-21101In

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionIonising radiation emittersCadherin 3 inhibitors

TargetsCadherin 3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPeptiDream Inc

China Registration ClassN/A

Develop Information

Active CompaniesPeptiDream Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A